Expanded Access Treatment Protocol CA204-143
NCT02368301 · Status: NO_LONGER_AVAILABLE · Type: EXPANDED_ACCESS
Last updated 2023-11-30
Summary
The objective of this expanded access program is to provide treatment with elotuzumab in combination with lenalidomide and dexamethasone for patients with relapsed or refractory multiple myeloma at U.S. sites where licensed physicians determine clinical need.
Conditions
Interventions
- DRUG
-
Elotuzumab in combination with Lenalidomide and Dexamethasone
Elotuzumab in Combination With Lenalidomide Plus Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma
Sponsors & Collaborators
- lead INDUSTRY
Principal Investigators
-
Bristol-Myers Squibb · Bristol-Myers Squibb
Eligibility
- Min Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
More Related Trials
-
Expanded Access Single Named Patient Program With Elotuzumab (BMS-901608) for the Treatment of Patient R-A With Relapsed/Refractory Multiple Myeloma
NCT02541643 ·Status: NO_LONGER_AVAILABLE
-
Japanese Study of BMS-901608 (Elotuzumab) in Combination With Lenalidomide and Low Dose Dexamethasone
NCT01241292 ·Status: COMPLETED ·Phase: PHASE1
-
Study of Safety of Elotuzumab Administered Over Approximately 60 Minutes in Combination With Lenalidomide and Dexamethasone for Newly Diagnosed or Relapsed/Refractory Multiple Myeloma Patients
NCT02159365 ·Status: COMPLETED ·Phase: PHASE2
-
Study of Elotuzumab in Combination With Lenalidomide and Dexamethasone in Subjects With Multiple Myeloma and Various Levels of Renal Function
NCT01393964 ·Status: COMPLETED ·Phase: PHASE1
-
An Exploratory Study to Evaluate the Combination of Elotuzumab and Nivolumab With and Without Pomalidomide in Relapsed Refractory Multiple Myeloma
NCT03227432 ·Status: WITHDRAWN ·Phase: PHASE2
-
PH III Study of Lenalidomide and Dexamethasone With or Without Elotuzumab to Treat Previously Untreated Multiple Myeloma (ELO 1 Substudy)
NCT01891643 ·Status: TERMINATED ·Phase: PHASE3
-
Continuing Treatment for Participants Who Have Participated in a Prior Protocol Investigating Elotuzumab
NCT02719613 ·Status: COMPLETED ·Phase: PHASE2
-
A Study of Elotuzumab With Pomalidomide, Bortezomib, and Dexamethasone in Relapsed Multiple Myeloma
NCT02718833 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2
-
Phase II Study of Lenalidomide/Dexamethasone With or Without Elotuzumab for Newly Diagnosed MM Patients in Japan
NCT02272803 ·Status: COMPLETED ·Phase: PHASE2
-
LCI-HEM-MYE-CRD-002: Carfilzomib-Revlimid-Dexamethasone-Elotuzumab in Relapsed/Refractory Multiple Myeloma
NCT03361306 ·Status: COMPLETED ·Phase: PHASE2
-
Early Patient Access Single Named Patient Program for the Use of Ulocuplumab for the Treatment of Multiple Myeloma
NCT02666209 ·Status: NO_LONGER_AVAILABLE
-
Phase III Study of Lenalidomide and Dexamethasone With or Without Elotuzumab to Treat Relapsed or Refractory Multiple Myeloma
NCT01239797 ·Status: COMPLETED ·Phase: PHASE3
-
Combination Study for High Risk Multiple Myeloma Patients
NCT03104270 ·Status: TERMINATED ·Phase: PHASE2
-
Study of Bortezomib,Lenalidomide,Dexamethasone & Elotuzumab in Newly Diagnosed MM
NCT02375555 ·Status: COMPLETED ·Phase: PHASE2
-
Bortezomib, Lenalidomide, and Dexamethasone Combination Therapy for Patients With Relapsed or Relapsed and Refractory Multiple Myeloma
NCT00378209 ·Status: COMPLETED ·Phase: PHASE2
-
Phase III Study of Lenalidomide and Dexamethasone With or Without Elotuzumab to Treat Newly Diagnosed, Previously Untreated Multiple Myeloma
NCT01335399 ·Status: COMPLETED ·Phase: PHASE3
-
Elotuzumab and Lenalidomide After Stem Cell Transplant in Treating Patients With Newly Diagnosed Multiple Myeloma
NCT02420860 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2
-
Elotuzumab + Iberdomide + Dexamethasone Post Ide-Cel in RRMM
NCT06518551 ·Status: RECRUITING ·Phase: PHASE1/PHASE2
-
A Study of Elotuzumab in Combination With Pomalidomide and Low Dose Dexamethasone and Elotuzumab in Combination With Nivolumab in Patients With Multiple Myeloma Relapsed or Refractory to Prior Treatment With Lenalidomide.
NCT02612779 ·Status: COMPLETED ·Phase: PHASE2
-
Elotuzumab in Autologous Stem Cell Transplantation (ASCT) and Lenalidomide Maintenance for Multiple Myeloma
NCT02655458 ·Status: COMPLETED ·Phase: PHASE1
-
Elotuzumab, CC-92480, and Dexamethasone for the Treatment of Relapsed or Refractory Myeloma After CD38- and BCMA-Targeted Therapies
NCT05981209 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE1
-
Safety Study of Elotuzumab in Combination With Thalidomide and Dexamethasone in Relapsed and/or Refractory Multiple Myeloma
NCT01632150 ·Status: COMPLETED ·Phase: PHASE2
-
Elotuzumab in Patients With Multiple Myeloma Before and After Peripheral Stem Cell Autologous Graft
NCT03393273 ·Status: WITHDRAWN ·Phase: PHASE2
-
Expanded Access to Elotuzumab (Empliciti) for Multiple Myeloma
NCT03126617 ·Status: NO_LONGER_AVAILABLE
-
A Study to Evaluate the Safety of Empliciti® (Elotuzumab) When Treating Patients With Multiple Myeloma in Taiwan
NCT06163040 ·Status: COMPLETED